Analysts Set Oruka Therapeutics, Inc. (NASDAQ:ORKA) Price Target at $131.30

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been given a consensus recommendation of “Moderate Buy” by the eleven ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and ten have given a buy recommendation to the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $131.30.

Several brokerages have issued reports on ORKA. Wedbush set a $165.00 target price on Oruka Therapeutics in a research report on Monday, April 27th. UBS Group raised their target price on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a “buy” rating in a research report on Tuesday, April 28th. Wall Street Zen raised Oruka Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, April 21st. Finally, Guggenheim set a $200.00 target price on Oruka Therapeutics and gave the stock a “buy” rating in a research report on Monday, April 27th.

Insider Transactions at Oruka Therapeutics

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,641 shares of the firm’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $40.91, for a total value of $312,593.31. Following the transaction, the insider directly owned 33,377 shares of the company’s stock, valued at approximately $1,365,453.07. This trade represents a 18.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Arjun Agarwal sold 10,290 shares of the firm’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $59.07, for a total value of $607,830.30. Following the completion of the transaction, the senior vice president directly owned 16,406 shares in the company, valued at $969,102.42. The trade was a 38.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 139,055 shares of company stock valued at $8,095,785. Company insiders own 23.49% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Royal Bank of Canada lifted its position in shares of Oruka Therapeutics by 47.2% during the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock valued at $34,000 after buying an additional 365 shares in the last quarter. Kennedy Capital Management LLC lifted its position in shares of Oruka Therapeutics by 0.9% during the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock valued at $1,476,000 after buying an additional 420 shares in the last quarter. AlphaCentric Advisors LLC lifted its position in shares of Oruka Therapeutics by 5.8% during the 1st quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company’s stock valued at $564,000 after buying an additional 626 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of Oruka Therapeutics by 35.0% during the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock valued at $92,000 after buying an additional 788 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Oruka Therapeutics by 62.4% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock valued at $71,000 after buying an additional 904 shares in the last quarter. 56.44% of the stock is owned by hedge funds and other institutional investors.

Oruka Therapeutics Stock Performance

NASDAQ ORKA opened at $68.47 on Friday. Oruka Therapeutics has a one year low of $10.77 and a one year high of $91.00. The stock has a 50-day moving average of $63.01 and a 200 day moving average of $43.76. The company has a market capitalization of $4.13 billion, a price-to-earnings ratio of -35.29 and a beta of -0.26.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.04. On average, equities analysts predict that Oruka Therapeutics will post -2.06 earnings per share for the current fiscal year.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.